VKTX

24.7704.14%
MM

Michael Morneau

Vice President of Finance & Administration

Mr. Michael Morneau serves as Vice President of Finance and Administration of Viking Therapeutics, Inc. since April 06, 2018 and served as its Chief Financial Officer until April 06, 2018. Mr. Morneau has over 25 years of accounting and financial experience at public and private companies in the biotechnology and accounting industries. Prior to Viking, from 2009 to 2014, he was VP of Finance and Chief Accounting Officer at Trius Therapeutics, Inc., a subsidiary of Cubist Pharmaceuticals, Inc., a pharmaceutical company, following Cubist’s acquisition of Trius in September 2013. Prior to Trius, from 2008 to 2009, he was Director of Lilly Research Labs Finance at Eli Lilly and Company, a pharmaceutical company. Prior to Eli Lilly, from 2006 to 2008, he was Director of Finance and Accounting at SGX Pharmaceuticals, Inc., a biotechnology company, which was acquired by Eli Lilly. Prior to SGX, from 2004 to 2006, he was Controller at Momenta Pharmaceuticals, Inc., a biotechnology company. Prior to Momenta, from 2002 to 2004, he was Controller at Gensym Corporation, a software company. Prior to Gensym, from 1992 to 2001, he worked at PricewaterhouseCoopers, LLP in the Audit Assurance Group, the last five years of which he was Manager of Business Assurance. Mr. Morneau earned his MBA and MA in accounting from New Hampshire College, and a BA in mathematics from the University of New Hampshire.

Positions